Repros Therapeutics is touting new data that shows patients taking Proellex in a mid-stage study experienced significantly less pain and less menstrual bleeding associated with uterine fibroids. Patients in the trial had an average score of 100 on a blood loss scale. For patients taking doses of Proellex, the score was reduced to 16.9 for patients taking 12.5 mgs of the drug and six for patients taking 25 mgs.
- see this release for more
- read the AP report on the data